KPTI - Karyopharm Therapeutics EPS in-line beats on revenue

Karyopharm Therapeutics (KPTI): Q4 GAAP EPS of -$0.59 in-line.Revenue of $35.1M (+93.9% Y/Y) beats by $5.41M.Q4 XPOVIO net sales of $20.2M.The Company expects that its existing cash, cash equivalents and investments, and the revenue it expects to generate from XPOVIO product sales, as well as revenue generated from its license agreements, will be sufficient to fund its planned operations into late 2022.Press Release

For further details see:

Karyopharm Therapeutics EPS in-line, beats on revenue